Newron Pharmaceuticals has announced changes to its management team with the departure of chief executive Luca Benatti on 31 May.
Benatti, who is the Italian research and development company’s founder and has been ceo since 1999, will leave the company to pursue other interests, having overseen the completion of the Phase III programme for Parkinson’s disease drug safinamide and a new partnership with Zambon. During Benatti’s tenure, Newron has evolved from a private, discovery stage biotech company to a late-stage biopharmaceutical company.
As a result of Benatti’s decision to leave the company, the new management team will consist of Stefan Weber, ceo and member of the board of directors, who has been Newron’s cfo since 2005; Ravi Anand, chief medical officer since 2005; Marco Caremi, executive vice president business development, and Roberto Galli, vice president finance, both have been with the company since 2002.
Rolf Stahel, Patrick Langlois, Francesco Parenti, Hanns Moehler and Stefan Weber will serve on Newron’s board of directors.
